Sera Prognostics

Sera Prognostics is a leading women’s health company utilizing our proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. Sera’s vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs. Sera’s first commercial product, the PreTRM® Test, is the only broadly clinically validated, commercially available blood-based biomarker test to accurately predict the risk of preterm birth.

70.2
70.2
NaN
NaN
NaN
NaN
Links
Valuation
$
Funding
$ 100.00 M
$ 230.86 M
Statistics
NA

Sera Prognostics is a leading women’s health company utilizing our proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. Sera’s vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs. Sera’s first commercial product, the PreTRM® Test, is the only broadly clinically validated, commercially available blood-based biomarker test to accurately predict the risk of preterm birth.

Overview
Merck KGaAMerck KGaAMerck KGaAMerck KGaAMerck KGaA 
View All
0and0